Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Asieris Pharma Announces Positive Data from Bladder Cancer Drug Trial

publication date: Mar 14, 2016
Asieris Pharmaceuticals, located in Taizhou City and also known as Jiangsu Yahong, presented positive preliminary results from its ongoing Phase II clinical trial of APL-1202, an oral MetAP2 inhibitor, in patients with bladder cancer. Asieris is focused on making breakthroughs in cancer treatment by repurposing available drugs. APL-1202 is nitroxoline, a wide spectrum antibiotic with an anti-angiogenesis effect that has been used in several countries for about fifty years. Asieris presented the results at the European Association of Urology (EAU) 2016 Congress in Munich, Germany. More details....

Editor's Note: Asieris will be presenting at the ChinaBio® Partnering Forum in Suzhou, May 18-19, 2016.

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital